TY - JOUR
T1 - Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma
AU - Wang, M.
AU - Giralt, S.
AU - Delasalle, K.
AU - Handy, B.
AU - Alexanian, R.
N1 - Copyright:
Copyright 2012 Elsevier B.V., All rights reserved.
PY - 2007/6
Y1 - 2007/6
N2 - In a previous trial among 137 previously untreated patients with multiple myeloma, the combination of thalidomide-dexamethasone induced remission in 66% of patients, including complete remission in 13%. In an attempt to induce more frequent remissions, we added bortezomib to this program. Between 7/03 and 3/06, 38 newly diagnosed patients with multiple myeloma received at least one, but no more than 3, courses of bortezomib in a dose of 1.3 mg/m 2 IV ×4; dexamethasone 20 mg/m 2 PO for 4 days beginning on days 1, 9, 17; thalidomide 100 mg PO daily increasing to a maximum of 200 mg. There was rapid onset of remission in 33 patients (87%) including 6 patients with complete remission (16%). Most side effects were preventable, but otherwise were usually mild and reversible. After a median of 4 months, 25 eligible patients received intensive therapy with high-dose melphalan supported by autologous blood stem cells, so that the myeloma was in complete remission in 14 patients (37% of all patients). The combination of bortezomib-thalidomide-dexamethasone was a highly effective primary treatment for newly diagnosed patients with multiple myeloma.
AB - In a previous trial among 137 previously untreated patients with multiple myeloma, the combination of thalidomide-dexamethasone induced remission in 66% of patients, including complete remission in 13%. In an attempt to induce more frequent remissions, we added bortezomib to this program. Between 7/03 and 3/06, 38 newly diagnosed patients with multiple myeloma received at least one, but no more than 3, courses of bortezomib in a dose of 1.3 mg/m 2 IV ×4; dexamethasone 20 mg/m 2 PO for 4 days beginning on days 1, 9, 17; thalidomide 100 mg PO daily increasing to a maximum of 200 mg. There was rapid onset of remission in 33 patients (87%) including 6 patients with complete remission (16%). Most side effects were preventable, but otherwise were usually mild and reversible. After a median of 4 months, 25 eligible patients received intensive therapy with high-dose melphalan supported by autologous blood stem cells, so that the myeloma was in complete remission in 14 patients (37% of all patients). The combination of bortezomib-thalidomide-dexamethasone was a highly effective primary treatment for newly diagnosed patients with multiple myeloma.
KW - Autologous stem-cell transplantation
KW - Bortezomib
KW - Dexamethasone
KW - Multiple myeloma
KW - Thalidomide
UR - http://www.scopus.com/inward/record.url?scp=34250630470&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34250630470&partnerID=8YFLogxK
U2 - 10.1080/10245330701214236
DO - 10.1080/10245330701214236
M3 - Article
C2 - 17558699
AN - SCOPUS:34250630470
SN - 1024-5332
VL - 12
SP - 235
EP - 239
JO - Hematology
JF - Hematology
IS - 3
ER -